Member Info for Wigster77

Sod off Long1. You come on here mocking Synairgen investors, then tell us we should be happy. Crawl back under your rock you piece of scum.

I do appreciate your unwavering enthusiasm and optimism Manifesto and I hope you are proven to be correct. I would like nothing more than to buy you a pint at BigJohnny's while you repeated tell me "I told you so" :-)

I must agree. Synairgen seem to have no commercial acumen or indeed desire to get anything to market, so yes, an EUA at any time is a close to zero chance.

This fact will be especially gauling for us deep-in LTHs if there are gems in the SPRINTER, ACTIV2 and long Covid data, and is what I'm fearful of most...but expecting now.

To continue the football analogy (even though I'm really no fan of JVT)...it'd be like Synairgen buying Ronaldo and Messi and telling them they mustn't shoot for goal.

As to what influence Polygon could have? I'm skeptical of them. They'll want to get some money back for sure, but can't see them pi55ing about with a company so devoid of ambition for too long. Expect a swift exit May/June unless Synairgen grow some commercialisation balls.

Takeover? Possible. Might get an offer of 50p/share I suppose.

Caveat: these are the ramblings of someone with a bad back and sleep deprivation. I'll possibly be more positive on subsequent posts!!

GLA, DYOR etc and enjoy your day :-)

I'd imagine things would move a lot quicker if there was a deadly virus world-wide or something daft.

Waiteoxford: you can set up an alert on the Synairgen and/or ADVFN websites, which will Email you when an RNS comes through. I am expecting the next news to be a week or so before the conference mentioned below, but that's just a guess.

Good luck with the wedding, and don't be too hard on yourself...plenty of us got burnt with over-optimistic expectations for this stock. Let's hope something can be salvaged from it.

Let's hope these industry insiders bring their wallets:

https://www.fiercepharma.com/pharma/m-a-large-biotech-pharma-companies-will-have-1-7t-firepower-for-dealmaking-2022

(apologies for posting this link for the 3rd time, but it gives me hope when I see trillions mentioned :-) )

Ref JV: Prior to "that" RNS it seemed to me, admittedly as a layman, that Synairgen were making all the right moves in terms of commercialisation:- partnering with Ashfield Engage and media/commercial/ex big-Pharma guru Ray Jordan, lots of internal recruits with formidable sounding CVs and offices opening in strategic locations like Ireland and the US. And no doubt a few more things that I've forgotten...

If we were to take it that "it was the trial that failed, not SNG001", then upon (hopefully) excellent Activ-2 results and gems from the deep-dive Sprinter exercise and/or promising Long Covid data etc etc, would it not be the case that enough groundwork has already been done to re-start the things mentioned above in order to complete the initial commercialisation process quickly following what would be (again hopefully) a swiftly and granted EUA* and subsequent orders?

I write the above in a slight "devils advocate" way. Personally speaking, even with the partnerships mentioned above, my confidence in Synairgen be able to push anything to market is currently very low, clearly due to failed trials and the subsequent rather underwhelming RNS's. Maybe a bigger JV is the way forward, maybe a takeover a bit earlier (and therefore less lucrative) than we'd hoped would be best?.. but what ever the outcome, I just hope that we get the financial reward which is deserved rather than selling out on the cheap. And that we start saving lives of course...

*provided of course that Synairgen have the nous to actually apply for one...

If they're all good Aether, it's no less than £75/share for me. No low-balling me with £40-50 insults please Mr Big Pharma.

Amazing how one word can cause so much kerfuffle, when it was originally used in a question not a statement. Group hug all, we're all on the same side :-)

Anyway, maybe the word "urgently" would be better. I certainly hope that whatever Synairgen are doing, they are doing it with the aim of getting SNG001 to market with some alacrity so that lives can finally start being saved, rather than doing endless trials and research.

Anyone know of any such conferences happening in the next month or so?

Good first post here Palladin - I'm sure there's lots in it that many of us agree with.

I wasn't aware that Synairgen had someone on the organising committee for the upcoming conference...

"surely a company with nothing to report wouldn't be on this platform?"

...or a company whose drug has terminally failed, with no hope of a comeback.

IMO, forget any more trials and get the bleeding drug out there.

Surely to God there's enough previous data to cut, shut, slice and dice to show that the drug is safe and works, even if to more targeted groups of people.

Seek an EUA on this basis and continue collecting data whilst the drug is commercialised and out there if that's what the researchers want (there is precedent for this, and also other drugs recently granted EUAs on P2 results alone, as has been discussed on here...).

At this rate it'll be 2025 and Synairgen will be on their 50th trial, will finally be satisfied to go for an EUA and thousands of people who could have benefitted from SNG001 will be dead.

Meanwhile, investors on here will have either verbally jousted each other to death on this very forum or slowly lost the will to live.

Just had a quick look at the RNS at at work. First glance - appears positive.

As stated by WelshFalcon the "pre-evaluation of key results by an International Conference Committee" is interesting

The fact that Synairgen have been selected to present is clearly means that important people still see promise in the data

They keep banging the drum about the 36% death reduction, which is clearly the most important metric to prove.

Using the phrase "merits further investigation" again...would prefer "merits commercialisation", but must be patient I guess. This big meeting could be a good "sales pitch" for Synairgen.

Looking at "high risk patients" and "new sub-group analyses" shows as bad as the last RNS was it has, as expected, allowed Synairgen to look at targeting SNG001 more effectively.

We now have a deadline for the Sprinter results RNS - still could be any day, but must be 16th May latest

No mention of Activ-2, so that could be any time too, and looks like it would be analysed separately.

...just a quick skim so may have missed something. All IMO, DYOR and GLA :-)

Maybe Maud, the tea-lady, did manage to negotiate 25% off those PG-Tips after all...

Manifesto, I love your sense of optimism!! As for me, I'm preparing myself like a kid at Christmas. Expecting a new bike, Scalextric, IPhone, Xbox etc and actually receiving smellies, socks and a nice knitted sweater from Nan. In poo brown. 3 sizes too big.

In all seriousness, I would be surprised if it's any more than the a dead-pan regurgitation of "that' RNS, mentioning crunching of data, hoping to join yet more trials and possibly a company name-change...

All hail Trialairgen!!

Genuinely nice to hear that RM is still alive.

All hail Genedrive, the savior of all Synairgen investors. FFS.

Recommend this post if you think Doc should sell at 4:29pm on Tuesday. :-)

No one bothered about this then? Positive news isn't it?

https://twitter.com/niaidnews/status/1509615265260077058?s=21&t=T7x8JCx9IrOzEZtOhHnwAw
https://www.niaid.nih.gov/news-events/save-program

Good find SYN00GOLD